Peptic Ulcer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Disease Indication, By Distribution Channel, By Region and Competition, 2020-2030F

Description

The Global Peptic Ulcer Drugs Market will grow from USD 3.54 Billion in 2024 to USD 4.31 Billion by 2030 at a 3.32% CAGR. Peptic ulcer drugs comprise pharmaceutical agents formulated to treat open sores that develop on the lining of the stomach, small intestine, or esophagus, primarily resulting from *Helicobacter pylori* infection or prolonged use of nonsteroidal anti-inflammatory drugs. The market's expansion is fundamentally driven by the escalating global prevalence of *H. pylori* infections and the extensive use of NSAIDs.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 3.54 Billion
Market Size 2030	USD 4.31 Billion
CAGR 2025-2030	3.32%
Fastest Growing Segment	Proton Pump Inhibitors
Largest Market	North America

Key Market Drivers

The global peptic ulcer drugs market is significantly driven by the persistent high incidence of *Helicobacter pylori* infection. This bacterium is a primary etiological factor for peptic ulcer disease, necessitating targeted antimicrobial and acid-suppressing therapies for successful eradication and healing. The widespread nature of this infection ensures a continuous and substantial patient pool requiring diagnostic procedures and a comprehensive array of pharmaceutical interventions.

Key Market Challenges

A significant impediment to the sustained expansion of the global peptic ulcer drugs market is the escalating antibiotic resistance encountered in *Helicobacter pylori* eradication regimens. This challenge directly undermines the effectiveness of established first-line therapies, leading to suboptimal patient outcomes. When bacteria develop resistance to antibiotics, the standard treatment protocols become less efficacious, often necessitating longer treatment durations, the use of more complex drug combinations, or the administration of higher doses, all of which increase treatment burden and healthcare costs.

Key Market Trends

The global peptic ulcer drugs market is experiencing a significant shift towards Potassium-Competitive Acid Blockers (P-CABs), marking an advancement in acid suppression therapy. P-CABs offer benefits such as rapid onset and consistent acid suppression, addressing limitations of traditional proton pump inhibitors. Their integration into treatment protocols is expanding, especially for patients unresponsive to conventional therapies. According to the American Gastroenterological Association's Clinical Practice Update, published in January 2025, P-CABs are recommended in place of proton pump inhibitors for most patients with *Helicobacter pylori* and other conditions where initial therapies have failed.

Key Market Players

Daewoong Pharmaceutical Co., Ltd
Takeda Pharmaceutical Co., Ltd.
Pfizer Inc.
AstraZeneca plc.
RedHill Biopharma Ltd.
Zydus Lifesciences Limited
ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
Boehringer Ingelheim International GmbH
Eisai Co. Ltd.
Yuhan Corporation

Report Scope:

In this report, the Global Peptic Ulcer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptic Ulcer Drugs Market, By Product Type:

Proton Pump Inhibitors
Potassium-Competitive Acid Blocker (P-CAB)
Antacids
H2- Antagonist
Antibiotics
Ulcer Protective

Peptic Ulcer Drugs Market, By Disease Indication:

Gastitis
Gastric Ulcer
Duodenal Ulcer
Gastroesophageal Reflux Disease (GERD)

Peptic Ulcer Drugs Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
E-Commerce

Peptic Ulcer Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Peptic Ulcer Drugs Market.

Available Customizations:

Global Peptic Ulcer Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptic Ulcer Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker (P-CAB), Antacids, H2- Antagonist, Antibiotics, Ulcer Protective)
- 5.2.2. By Disease Indication (Gastitis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD))
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Peptic Ulcer Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By Disease Indication
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Peptic Ulcer Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By Disease Indication
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Peptic Ulcer Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By Disease Indication
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Peptic Ulcer Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By Disease Indication
    - 6.3.3.2.3. By Distribution Channel

7. Europe Peptic Ulcer Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By Disease Indication
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Peptic Ulcer Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By Disease Indication
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. France Peptic Ulcer Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By Disease Indication
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. United Kingdom Peptic Ulcer Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By Disease Indication
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Peptic Ulcer Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By Disease Indication
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Peptic Ulcer Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By Disease Indication
    - 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Peptic Ulcer Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By Disease Indication
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Peptic Ulcer Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By Disease Indication
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Peptic Ulcer Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By Disease Indication
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Peptic Ulcer Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By Disease Indication
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Peptic Ulcer Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By Disease Indication
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Peptic Ulcer Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By Disease Indication
    - 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Peptic Ulcer Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By Disease Indication
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Peptic Ulcer Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By Disease Indication
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. UAE Peptic Ulcer Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By Disease Indication
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. South Africa Peptic Ulcer Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By Disease Indication
    - 9.3.3.2.3. By Distribution Channel

10. South America Peptic Ulcer Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By Disease Indication
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Peptic Ulcer Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By Disease Indication
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Colombia Peptic Ulcer Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By Disease Indication
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. Argentina Peptic Ulcer Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By Disease Indication
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Peptic Ulcer Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Daewoong Pharmaceutical Co., Ltd
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Takeda Pharmaceutical Co., Ltd.
15.3. Pfizer Inc.
15.4. AstraZeneca plc.
15.5. RedHill Biopharma Ltd.
15.6. Zydus Lifesciences Limited
15.7. ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
15.8. Boehringer Ingelheim International GmbH
15.9. Eisai Co. Ltd.
15.10. Yuhan Corporation